KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Other financing activities (2021 - 2025)

Ginkgo Bioworks Holdings posted quarterly Other financing activities of $985000.0 for Q4 2025, up 12212.5% year-on-year from N/an in Q4 2024, and up 12212.5% on a QoQ basis from $8000.0 in Q4 2024.

Ginkgo Bioworks Holdings (DNA) has 5 years of Other financing activities data on file, last reported at $985000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities rose 12212.5% year-over-year to $985000.0; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (up 162.44% YoY), and the FY2025 full-year result was $1.3 million, up 33400.0% from the prior year.
  • Other financing activities for Q4 2025 stood at $985000.0, up from $8000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $34.1 million in Q3 2021 and bottomed at -$88000.0 in Q3 2022.
  • The 5-year median for Other financing activities is $155760.0 (2021), against an average of $5.7 million.
  • The widest annual swing landed in 2024, when Other financing activities tumbled 300.0%; it then jumped 12212.5% in 2025.
  • A 5-year view of Other financing activities shows it stood at -$67000.0 in 2021, then surged by 1582.09% to $993000.0 in 2022, then sank by 39.17% to $604000.0 in 2023, then tumbled by 98.68% to $8000.0 in 2024, then surged by 12212.5% to $985000.0 in 2025.
  • The last three Other financing activities figures came in at $985000.0 (Q4 2025), $8000.0 (Q4 2024), and -$4000.0 (Q3 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Ginkgo Bioworks Holdings 542.03 Mn 542.03 Mn 16.38 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 985,000.00
Dec 31, 2025 985,000.00
Dec 31, 2024 8,000.00
Dec 31, 2024 8,000.00
Sep 30, 2024 -4,000.00
Sep 30, 2024 -4,000.00
Dec 31, 2023 604,000.00
Dec 31, 2023 604,000.00
Sep 30, 2023 -1,000.00
Sep 30, 2023 -1,000.00
Dec 31, 2022 993,000.00
Dec 31, 2022 993,000.00
Sep 30, 2022 -88,000.00
Sep 30, 2022 -88,000.00
Dec 31, 2021 -67,000.00
Dec 31, 2021 -67,000.00
Sep 30, 2021 34.13 Mn
Sep 30, 2021 34.13 Mn
Jun 30, 2021 25.72 Mn
Jun 30, 2021 25.72 Mn
Mar 31, 2021 155,760.00
Mar 31, 2021 155,760.00